Veliz Marays, Pinilla-Ibarz Javier
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
J Blood Med. 2011;2:71-7. doi: 10.2147/JBM.S13063. Epub 2011 May 2.
The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine. Preclinical data showed improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab. Clinical studies have shown single-agent activity for ofatumumab in CLL and in other low-grade non-Hodgkin's lymphomas. Combination studies are being conducted to enhance the therapeutic efficacy of ofatumumab. This paper reviews some of the key clinical studies that led to approval of ofatumumab, and future directions.
在过去十年中，随着抗CD20单克隆抗体被纳入治疗手段，慢性淋巴细胞白血病（CLL）的管理有了显著改善。奥法木单抗是一种新型抗CD20单克隆抗体，最近在美国和欧洲被批准用于治疗对阿仑单抗和氟达拉滨耐药的CLL。临床前数据显示，与利妥昔单抗相比，其补体依赖的细胞毒性和抗体依赖的细胞毒性有所改善。临床研究表明，奥法木单抗在CLL和其他低度非霍奇金淋巴瘤中具有单药活性。目前正在进行联合研究以提高奥法木单抗的治疗效果。本文回顾了一些促成奥法木单抗获批的关键临床研究以及未来的发展方向。
